Piper Sandler Adjusts Price Target on Viatris to $14 From $13
Piper Sandler has updated its price target for Viatris Inc., raising it from $13 to $14.
Stocks · News reference
Viatris Addresses Supply Demand for Estradiol Products
Viatris reported a significant surge in demand for its estradiol patches and creams and detailed steps taken to increase production capacity.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
JPMorgan Adjusts Viatris Price Target to $20
JPMorgan Chase has raised its price target for Viatris Inc. from $18 to $20 while maintaining a neutral rating on the stock.
Viatris Receives FDA Approval For RYZUMVI To Treat Presbyopia In Adults
Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in